- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Moleculin Biotech Inc (MBRX)
Moleculin Biotech Inc stock price live, this page displays NASDAQ MBRX stock exchange data. View the MBRX premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Moleculin Biotech Inc real time stock price chart below.
What Is the Moleculin Biotech Inc Stock Price Today?
The Moleculin Biotech Inc stock price today is 0.673.
What Is the Stock Symbol for Moleculin Biotech Inc?
The stock symbol for Moleculin Biotech Inc is ""MBRX.""
What Stock Exchange Does Moleculin Biotech Inc Trade On?
Moleculin Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is Moleculin Biotech Inc a Good Stock to Buy?
Determining whether Moleculin Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MBRX quote. (ISIN: US60855D3098)
What Is the Moleculin Biotech Inc Stock Price Today?
The Moleculin Biotech Inc stock price today is 0.673.
What Is the Stock Symbol for Moleculin Biotech Inc?
The stock symbol for Moleculin Biotech Inc is ""MBRX.""
What Stock Exchange Does Moleculin Biotech Inc Trade On?
Moleculin Biotech Inc is listed and trades on the NASDAQ stock exchange.
Is Moleculin Biotech Inc a Good Stock to Buy?
Determining whether Moleculin Biotech Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the MBRX quote. (ISIN: US60855D3098)
NASDAQ
Currency in USD
0.673
-0.011(-1.67%)
Real-time Data·
Fair Value
An estimate of a Moleculin Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.664
0.730
52 wk Range
0.250
3.650
MBRX Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
MBRX is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Moleculin Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.6640.730
52 wk Range
0.2503.650
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
MBRX Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Moleculin Biotech's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PricePrice Target
7.000
Upside
+940.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Buy
Moleculin Biotech Inc Company Profile
Moleculin Biotech, Inc., a late-stage pharmaceutical development company, engages in the development of therapeutic candidates for the treatment of tumors and viruses. Its lead drug candidate is Annamycin, an anthracycline, which is in clinical stage for the treatment of relapsed or refractory acute myeloid leukemia and soft tissue sarcoma lung metastases. The company is also developing WP1066 portfolio, including WP1066, WP1193, and WP1220, which are immune/transcription modulators designed to inhibit phosphorylated signal transducer and activator of transcription for brain tumors and pancreatic and other cancers. In addition, it is developing WP1122 portfolio, such as WP1122, WP1096, and WP1097 designed to exploit the uses of inhibitors of glycolysis comprising 2-deoxy-D-glucose for the treatment of pathogenic viruses and various cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.
Moleculin Biotech Inc Earnings Call Summary for Q1/2025
- Moleculin ended Q1 with $8M cash, funding operations into Q3 2025; needs additional $15M for Q1 2026
- Initiated Phase 3 MIRACLE trial for Anamycin; expanded to 38 sites globally; EMA approval in 9 EU countries
- Stock declined 5.54% post-call, closing at $1.07; 78% drop over past year; beta of 1.64 indicates high volatility
- Expects data from initial 45-patient cohort by end of 2025; analyst price targets range from $4 to $20
- CEO highlights Anamycin as potentially first non-cardiotoxic anthracycline; WP1066 IV formulation update expected year-end
Last Updated: 14/05/2025, 15:16
Read Full TranscriptCompare MBRX to Peers and Sector
Metrics to compare | MBRX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipMBRXPeersSector | |
|---|---|---|---|---|
P/E Ratio | −0.9x | −3.4x | −0.5x | |
PEG Ratio | −0.01 | 0.00 | 0.00 | |
Price/Book | 499.9x | 2.9x | 2.6x | |
Price / LTM Sales | - | 161.8x | 3.3x | |
Upside (Analyst Target) | - | 175.8% | 42.8% | |
Fair Value Upside | Unlock | −0.7% | 6.5% | Unlock |
Analyst Ratings
3 Buy
0 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.000
(+940.12% Upside)
Earnings
Latest Release
Mar 21, 2025
EPS / Forecast
-2.85 / -0.17
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Stock Exchange Does Moleculin Biotech Trade On?
Moleculin Biotech is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Moleculin Biotech?
The stock symbol for Moleculin Biotech is "MBRX."
What Is the Moleculin Biotech Market Cap?
As of today, Moleculin Biotech market cap is 20.42M.
What Is Moleculin Biotech's Earnings Per Share (TTM)?
The Moleculin Biotech EPS (TTM) is -4.50.
From a Technical Analysis Perspective, Is MBRX a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
How Many Times Has Moleculin Biotech Stock Split?
Moleculin Biotech has split 2 times.
How Many Employees Does Moleculin Biotech Have?
Moleculin Biotech has 17 employees.
What is the current trading status of Moleculin Biotech (MBRX)?
As of 06 Aug 2025, Moleculin Biotech (MBRX) is trading at a price of 0.67, with a previous close of 0.69. The stock has fluctuated within a day range of 0.66 to 0.73, while its 52-week range spans from 0.25 to 3.65.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.